Vontobel Holding’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$393K Hold
5,240
﹤0.01% 921
2025
Q4
$415K Buy
+5,240
New +$395K ﹤0.01% 1052
2025
Q1
Sell
-5,865
Closed -$205K 1123
2024
Q4
$205K Buy
5,865
+363
+7% +$13.6K ﹤0.01% 1011
2024
Q3
$220K Sell
5,502
-2,483
-31% -$116K ﹤0.01% 992
2024
Q2
$381K Buy
7,985
+488
+7% +$20K ﹤0.01% 846
2024
Q1
$325K Sell
7,497
-713
-9% -$34K ﹤0.01% 887
2023
Q4
$415K Sell
8,210
-6
-0.1% -$287 ﹤0.01% 845
2023
Q3
$373K Sell
8,216
-350
-4% -$14.4K ﹤0.01% 843
2023
Q2
$351K Sell
8,566
-1,250
-13% -$48K ﹤0.01% 886
2023
Q1
$351K Sell
9,816
-1,113
-10% -$41.8K ﹤0.01% 854
2022
Q4
$406K Sell
10,929
-353
-3% -$14.8K ﹤0.01% 811
2022
Q3
$499K Sell
11,282
-2,928
-21% -$123K 0.01% 716
2022
Q2
$534K Sell
14,210
-505
-3% -$19K 0.01% 700
2022
Q1
$545K Buy
14,715
+3,405
+30% +$111K ﹤0.01% 768
2021
Q4
$344K Buy
+11,310
New +$356K ﹤0.01% 898

Other funds holding IONS

Vontobel Holding's IONS Position: Q1 2026 in Review

Vontobel Holding held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 5,240 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #921.

Vontobel Holding first reported a position in IONS in Q4 2021 and has held it in 15 quarters since. The position peaked at $545K in Q1 2022. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Vontobel Holding held 5,240 shares of Ionis Pharmaceuticals worth $393K as of Q1 2026.
  • Vontobel Holding left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #921 holding.
  • Vontobel Holding first reported a position in Ionis Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Vontobel Holding's Ionis Pharmaceuticals position peaked at $545K in Q1 2022.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.